Endometrial Cancer News and Research RSS Feed - Endometrial Cancer News and Research

Smoking-related DNA damage can be detected in cheek swabs

Smoking-related DNA damage can be detected in cheek swabs

DNA damage caused by smoking can be detected in cheek swabs, finds research published today in JAMA Oncology. The study provides evidence that smoking induces a general cancer program that is also present in cancers which aren't usually associated with it - including breast and gynaecological cancers. [More]
Obese people at greater risk of developing cancer

Obese people at greater risk of developing cancer

Cancer is more likely to develop in people who are very overweight (obese), because surplus body fat interferes with various hormone cycles and with glucose and fat metabolism. On the occasion of European Obesity Day this coming Saturday (16 May), metabolic expert Alexandra Kautzky-Willer, Comprehensive Cancer Center at MedUni Vienna and Vienna General Hospital, draws attention to the fact that, even in Austria, more and more people are suffering from obesity. [More]
Gynecologic oncologist awarded grant to improve quality of life for women with endometrial cancer

Gynecologic oncologist awarded grant to improve quality of life for women with endometrial cancer

The Patient-Centered Outcomes Research Institute Board of Governors recently awarded more than $2.7 million in contracted funding to Katina Robison, MD, a gynecologic oncologist with the Program in Women's Oncology at Women & Infants Hospital of Rhode Island, a Care New England hospital, for the study "Cancer of the Uterus and Treatment of Stress Incontinence." [More]
Brachytherapy improves overall survival for women with inoperable early stage endometrial cancer

Brachytherapy improves overall survival for women with inoperable early stage endometrial cancer

Women who have early stage endometrial cancer and are inoperable tend to live longer if they have been treated with brachytherapy with or without external beam radiation, according to new research to be presented at the 3rd ESTRO Forum in Barcelona, Spain, on Sunday. [More]
Medical University of Vienna study supports use of ANGLE's Parsortix system for ovarian cancer study

Medical University of Vienna study supports use of ANGLE's Parsortix system for ovarian cancer study

ANGLE plc, the specialist medtech company, is delighted to announce that the Medical University of Vienna, one of its key opinion leaders, has published highly encouraging results in support of the use of ANGLE's Parsortix system in the detection of ovarian cancer. [More]
Researchers discover new biomarker to identify women with uterine cancer

Researchers discover new biomarker to identify women with uterine cancer

Researchers at Uppsala University have, together with researchers from Turku and Bergen, discovered a new biomarker which makes it possible to identify women with uterine cancer who have a high risk of recurrence. [More]
Aeterna Zentaris inks Material Transfer Agreement with MUSC

Aeterna Zentaris inks Material Transfer Agreement with MUSC

Aeterna Zentaris Inc. today announced that it has agreed to transfer its discovery library of roughly 100,000 unique compounds to the South Carolina Center for Therapeutic Discovery & Development (the Center) pursuant to a just concluded Material Transfer Agreement. [More]
Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

Caris Life Sciences today announced the presentation of a study that found drugs targeting specific pathways may have potentially significant benefit in a select subset of patients with uterine cancer. The study results were highlighted today in an oral presentation in a Plenary Session at the Society of Gynecologic Oncology 2015 Annual Meeting on Women's Cancer in Chicago, Ill. [More]
DNA samples collected from tampons may help detect endometrial cancer

DNA samples collected from tampons may help detect endometrial cancer

Researchers at Mayo Clinic have shown that it is possible to detect endometrial cancer using tumor DNA picked up by ordinary tampons. The new approach specifically examines DNA samples from vaginal secretions for the presence of chemical "off" switches — known as methylation — that can disable genes that normally keep cancer in check. [More]
Many women fail to understand risks of unapproved, untested bioidentical hormone therapies

Many women fail to understand risks of unapproved, untested bioidentical hormone therapies

From 28% to 68% of women using hormones at menopause take compounded, so-called "bioidentical" hormones, but women don't understand the risks of these unapproved, untested treatments, shows an analysis of two large surveys, which was published online today in Menopause, the journal of The North American Menopause Society. [More]
Study: Risk of uterine sarcoma fairly low in women following hysterectomy

Study: Risk of uterine sarcoma fairly low in women following hysterectomy

Uterine sarcoma - a potentially aggressive type of cancer that forms in tissues in the uterus - was found in 0.22 % of women following a hysterectomy for benign conditions, a new large-scale study by the University of Michigan departments of Obstetrics and Gynecology, and Surgery finds. [More]
Risk of ovarian cancer increased with even short-term HRT use

Risk of ovarian cancer increased with even short-term HRT use

There has been much uncertainty regarding the risk of cancer associated with taking hormone replacement therapy (HRT) for the menopause. An analysis of all available evidence published in The Lancet today shows that HRT, even when taken for only a few years, significantly increases the risk of developing the two most common types of ovarian cancer. [More]
Final Phase 1 data of zoptarelin doxorubicin Phase 1/2 trial published in Clinical Cancer Research

Final Phase 1 data of zoptarelin doxorubicin Phase 1/2 trial published in Clinical Cancer Research

Aeterna Zentaris Inc. today announced that an article on final data for the Phase 1 portion of the ongoing Phase 1/2 trial in prostate cancer with zoptarelin doxorubicin (formerly AEZS-108), a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin, has been published in the December issue of Clinical Cancer Research. [More]
Preventive effect of tamoxifen drug for breast cancer remains virtually constant for 20 years

Preventive effect of tamoxifen drug for breast cancer remains virtually constant for 20 years

The preventive effect of breast cancer drug 'tamoxifen' remains virtually constant for at least 20 years - with rates reduced by around 30 per cent - new analysis published in The Lancet Oncology reveals. [More]
Study shows how exosomes secreted by tumor cells promote tumor growth

Study shows how exosomes secreted by tumor cells promote tumor growth

Researchers at the Bellvitge Biomedical Research Institute of Bellvitge, the Catalan Institute of Oncology and the University Hospital of Bellvitge have participated in an international study published in the journal Cancer Cell that describes how exosomes secreted by tumor cells contain protein and microRNA molecules capable of transform neighboring cells into tumoral cells promoting tumor growth. [More]
RNF43 mutation may serve as biomarker that identifies colorectal, endometrial cancer patients

RNF43 mutation may serve as biomarker that identifies colorectal, endometrial cancer patients

Scientists say they have identified in about 20 percent of colorectal and endometrial cancers a genetic mutation that had been overlooked in recent large, comprehensive gene searches. With this discovery, the altered gene, called RNF43, now ranks as one of the most common mutations in the two cancer types. [More]
New research may help identify individuals at increased risk of pancreatic cancer

New research may help identify individuals at increased risk of pancreatic cancer

New research that provides a better understanding of pancreatic cancer may help identify individuals at increased risk. The findings are published early online in Cancer, a peer-reviewed journal of the American Cancer Society. [More]
ERK and JNK enzymes may offer solutions for treating endometrial, colon cancers

ERK and JNK enzymes may offer solutions for treating endometrial, colon cancers

In the quest to solve cancer's mysteries, they come in handy when describing tongue-twisting processes and pathways that somehow allow tumors to form and thrive. Two examples are ERK (extracellular-signal-related kinase) and JNK (c-June N-Terminal Kinase), enzymes that may offer unexpected solutions for treating some endometrial and colon cancers. [More]
RT with concurrent chemotherapy post surgery is effective for treating endometrial cancer

RT with concurrent chemotherapy post surgery is effective for treating endometrial cancer

Radiation therapy with concurrent paclitaxel chemotherapy following surgery is an effective treatment for patients with high-risk endometrial cancer, according to a study published in the September 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO). [More]
Scientists identify genetic mutations in endometrioid endometrial carcinoma

Scientists identify genetic mutations in endometrioid endometrial carcinoma

Parents of twins often tell them apart through subtle differences such as facial expression, moles, voice tone and gait. Similarly, physicians treating women with endometrial cancer must be able to distinguish between different versions of this disease form that, on the surface, appear the same. [More]
Advertisement
Advertisement